Global Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables and Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales) – Industry Trends and Forecast to 2031.
Lung Cancer Diagnostics Market Analysis and Size
Early detection is a major feature of the lung cancer diagnostics market, offering the capability to identify lung cancer at its nascent stages when treatment interventions are most effective. Through advanced screening programs and diagnostic tests such as low-dose CT scans and molecular testing, healthcare providers can detect lung cancer in high-risk individuals or those displaying early symptoms. Early detection enhances patient outcomes by enabling timely treatment initiation and reduces healthcare costs associated with advanced-stage disease management.
For Instance,
According to the National Center for Biotechnology Information (NCBI), surgical resection of early-stage non-small cell lung cancer (NSCLC) can yield favorable 5-year survival rates of up to 70%. However, the majority of patients are diagnosed with advanced-stage disease, where survival rates remain poor despite advancements in oncological management. A report from NCBI highlights UK statistics showing a stark difference in 1-year survival rates between stage I (81-85%) and stage IV (15-19%) lung cancer patients, emphasizing the critical need for improved early detection strategies to enhance patient outcomes and reduce mortality rates.
Global lung cancer diagnostics market size was valued at USD 2.97 billion in 2023 and is projected to reach USD 8.59 billion by 2031, with a CAGR of 14.2% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Lung Cancer Diagnostics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024-2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Instruments, Consumables and Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. HoffmannLa Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), Quest Diagnostics Incorporated (U.S.), Biodesix (U.S.), Amoy Diagnostics Co., Ltd. (China), BioRad Laboratories, Inc. (U.S.), Biocartis (Belgium), Boditech Med Inc. (South Korea), Danaher (U.S.), Vela Diagnostics (Singapore), DiaSorin S.p.A. (Italy), Exact Sciences UK, Ltd. (U.K.), Guardant Health (U.S.), LalPathLabs (India), LungLife AI, Inc. (U.S.), MedGenome (India), Myriad Genetics, Inc. (U.S.), NeoGenomics Laboratories (U.S.), NanoString Technology (U.S.), Nanoentek (South Korea), Oncocyte Corporation (U.S.), PlexBio Co. Ltd. (Taiwan), QIAGEN (Germany), Siemens Healthcare GmbH (Germany), Veracyte, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Lung cancer is a malignant tumor that originates in the cells of the lungs, typically in the lining of the bronchi or the alveoli. It is primarily caused by long-term exposure to substances such as cigarette smoke, asbestos, and air pollution. Lung cancer is categorized into two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), each with distinct characteristics and treatment approaches. Symptoms may include persistent cough, chest pain, shortness of breath, coughing up blood, and unexplained weight loss. Lung cancer is one of the most common cancers worldwide and a leading cause of cancer-related mortality.
Lung Cancer Diagnostics Market Dynamics
Drivers
- Growing Technological Advancements Enhances Reliability of Diagnostic Methods
Innovations in imaging technologies, such as computed tomography (CT) scans and positron emission tomography (PET) scans, enable early detection of lung nodules and metastases. Advancements in molecular diagnostics, including next-generation sequencing (NGS) and liquid biopsy techniques, facilitate the identification of specific genetic mutations and biomarkers associated with lung cancer. These technological breakthroughs improve diagnostic accuracy and enable personalized treatment strategies tailored to individual patients, thereby driving the demand for advanced diagnostic tools and services in the lung cancer diagnostics market.
For Instance,
In October 2023, DELFI Diagnostics' launch of FirstLook Lung represents a significant advancement in lung cancer diagnostics. While introducing a routine blood test for lung cancer screening, FirstLook Lung offers a non-invasive and accessible method for early detection. This innovative technology utilizes molecular diagnostics and biomarker analysis to enhance the accuracy of screening, aligning with the trend of technological advancements driving the lung cancer diagnostics market. The availability of such a convenient and precise screening tool improves early detection rates and underscores the importance of leveraging cutting-edge technologies to combat lung cancer effectively.
- Growing Awareness of Early Detection and Screening for Lung Cancer Leads to Better Disease Management
As public education campaigns raise awareness about risk factors such as smoking and environmental pollutants, individuals are more expected to seek preventive healthcare measures, including regular screenings. Advocacy efforts by healthcare organizations and patient groups further amplify awareness, prompting healthcare providers to prioritize lung cancer screening and diagnosis in their practice. Growing awareness plays a pivotal role in driving the uptake of lung cancer diagnostics, ultimately contributing to better disease management and reduced mortality rates.
Opportunities
- Rising Aging Population Leads to Growing Demand of Specialized Diagnostic Solutions
As people age, their risk of developing lung cancer increases, driving the demand for diagnostic tests and screening programs tailored to this demographic. Additionally, older adults often experience comorbidities and may have unique healthcare needs, necessitating comprehensive diagnostic approaches that consider age-related factors. The growing aging population in many regions, particularly in developed countries, creates a steady demand for lung cancer diagnostics, offering opportunities for market expansion and the development of specialized diagnostic solutions targeting this demographic.
- Increasing Investments in Research and Development promotes the Demand for Scalable Screening Programs
Research and development investments fuel innovation, leading to the development of advanced diagnostic technologies and novel biomarkers for early detection and accurate diagnosis of lung cancer. As R&D efforts progress, there is potential for the introduction of more cost-effective and efficient diagnostic solutions, addressing the growing demand for accessible and scalable screening programs. Furthermore, collaborations between academia, industry, and government entities foster interdisciplinary approaches, accelerating the translation of research findings into clinical applications. Ultimately, these investments pave the way for improved patient outcomes, reduced healthcare burden, and enhanced strategies for combating lung cancer globally.
Restraints/Challenges
- High Costs Associated with Lung Cancer Diagnostics limits Diagnostic Procedures
Advanced diagnostic techniques such as molecular testing and imaging modalities can be expensive, placing financial burdens on patients and healthcare systems asuch as. These costs may deter individuals from seeking timely screenings or diagnostic tests, resulting in delayed diagnosis and poorer outcomes. Additionally, limited reimbursement coverage for certain diagnostic procedures further exacerbates the affordability issue, particularly for uninsured or underinsured populations.
- Stringent Regulatory Approval Delays Introduction of Innovative Diagnostic Solutions
The approval process poses a significant restraint on the lung cancer diagnostics market. Developing and commercializing new diagnostic tests and technologies for lung cancer requires extensive clinical validation and regulatory clearance, which can be time-consuming and resource-intensive. Delays in obtaining regulatory approval prolong the time to market entry, hindering the introduction of innovative diagnostic solutions. Moreover, the complexity of regulatory requirements may deter smaller companies with limited resources from pursuing development efforts, limiting the diversity and competitiveness of the market.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global laboratory information management systems (LIMS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In August 2022, F. Hoffmann-La Roche Ltd. launched the Digital LightCycler System, a cutting-edge digital PCR system aiding clinical researchers in comprehending cancer, genetic diseases, and infections. This system enhances DNA and RNA analysis precision, specifically tailored for oncology and infectious disease laboratories
- In October 2022, Quest Diagnostics embarking on a renewed collaboration with Decode Health, marking a new phase in their partnership. This endeavor has streamlined the development of diagnostic tests and identification of novel medication targets for diverse cancers, while also bolstering Quest Diagnostics' global footprint
Lung Cancer Diagnostics Market Scope
The market is segmented on the basis of product type, test type, cancer type, end user, and distribution channel. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables and Accessories
Test Type
- Biomarkers Tests
- Imaging Test
- Biopsy
- Blood Test
- Others
Cancer Type
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
End User
- Hospital
- Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
Distribution Channel
- Direct Tender
- Retail Sales
Lung Cancer Diagnostics Market Regional Analysis/Insights
The market is analyzed, and market size insights and trends are provided by country, product type, test type, cancer type, end user, and distribution channel, as referenced above.
Some countries covered in the market are the U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Taiwan and Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Oman, Bahrain, Qatar, Kuwait and Rest of Middle East and Africa.
In North America, U.S. dominates in the market is anticipated due to a significant rise in awareness regarding early cancer detection and the importance of consultancy services. This heightened awareness has led to increased demand for advanced diagnostic technologies and services, driving market growth. Additionally, the U.S. boasts a robust healthcare infrastructure and a strong emphasis on research and development, further contributing to its leading position in cancer diagnostics. These factors collectively position the U.S. as a key player in shaping the future landscape of cancer diagnostics in North America.
In Europe, Germany is expected for growth in the lung cancer diagnostics market, driven by advancements in technology and the reliability of healthcare services. Germany's healthcare sector is renowned for its high standards and efficiency, which has instilled trust among patients and contributed to the adoption of diagnostic innovations. Additionally, the integration of healthcare data with portable devices enables personalized care and remote monitoring, enhancing diagnostic capabilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Lung Cancer Diagnostics Market Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- F. HoffmannLa Roche Ltd. (Switzerland)
- Thermo Fisher Scientific Inc. (U.S.)
- Abbott (U.S.)
- Quest Diagnostics Incorporated (U.S.)
- Biodesix (U.S.)
- Amoy Diagnostics Co., Ltd. (China)
- BioRad Laboratories, Inc. (U.S.)
- Biocartis (Belgium)
- Boditech Med Inc. (South Korea)
- Danaher (U.S.)
- Vela Diagnostics (Singapore)
- DiaSorin S.p.A. (Italy)
- Exact Sciences UK, Ltd. (U.K.)
- Guardant Health (U.S.)
- LalPathLabs.com (India)
- LungLife AI, Inc. (U.S.)
- MedGenome (India)
- Myriad Genetics, Inc. (U.S.)
- NeoGenomics Laboratories (U.S.)
- NanoString Technology (U.S.)
- Nanoentek (South Korea)
- Oncocyte Corporation (U.S.)
- PlexBio Co. Ltd. (Taiwan)
- QIAGEN (Germany)
- Siemens Healthcare GmbH (Germany)
- Veracyte, Inc. (U.S.)
SKU-